Roswell Park offers new ways to partner with us, innovations to match your goals, and breakthroughs that will change lives.

Founded in 1898 as the world’s first institution dedicated to cancer research, Roswell Park Comprehensive Cancer Center is uniquely focused on a disease that directly affects 1 in 3 people — and impacts the world.

Our focus on cancer has unleashed more than a century of discovery and innovation that led to the prostate cancer PSA screening test, photodynamic therapy, a simulator to train robotic surgeons, and the newly FDA-approved drug, Polivy,™ a targeted immunotherapy for lymphoma.

Our technologies

Tomorrow’s new cellular therapy, cancer drug, diagnostic or surgical device may already be here.

We have many innovations ready for advancement, development, licensing, and transfer to the marketplace.

Tech highlights
Drs Fenstermaker and Ciesielski

History of innovation

We hold 81 U.S. patents, 101 license agreements and have launched more than a dozen biotech spinoff companies.

See what we've done
OICO Education Program - student with microscope

Partnering with Roswell Park

Become part of the solution to one of the most difficult diseases and join in our vision for a world without cancer.

We can arrange an on-campus visit, presentation or meetings with our researchers.

Learn more
Technology and Innovation Info Sheet

Technology and innovation quick facts

Read more about the history of innovation at Roswell Park and explore how we may be able to work together.

Read more

Industry partnering

CAR t-cell

Roswell Park Comprehensive Cancer Center, Generate:Biomedicines enter into collaboration agreement to accelerate novel cell therapies for oncology using generative AI

Roswell Park and Generate:Biomedicines will contribute toward creating optimized cell therapies for up to three oncology targets, including ovarian cancer and other solid tumors.

Learn more

Two men in ties stand smiling in a sunlit lobby

Roswell Park licenses rapid, comprehensive blood test to Agilent, a global leader in the life sciences market.

PanHeme, an assay used to support the clinical care of patients with blood cancers, is a next-generation-sequencing technology that can identify mutations in hundreds of genes in under 72 hours.

Read the press release

Contact us

Phone: 716-845-1300, x6955

Magdalena Korzec
Administrative Assistant
Phone: 716-845-1300, x6996